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OBJECTIVES: The aim of the study was to estimate the eco-
nomic impact of improved pharmaceutical care in obstructive
airway diseases (OAD) by evaluating the effects of the introduc-
tion of new pharmaceutical treatments in the costs of OAD
treatment between 1996 and 2005. METHODS: To analyse the
real change in the costs of OAD treatment, we estimated costs in
2005 assuming that the treatment practices (pharmaceuticals,
hospitalizations, outpatient visits) had been similar to 1996 and
subsequently compared these expected costs to the actual costs in
2005. The change in real costs due to improved pharmaceutical
care was estimated by evaluating the change in the number of
exacerbations requiring treatment. A spreadsheet based probabi-
listic simulation model was used. The data on health care
resources, pharmaceuticals and costs were obtained from
national registries. The effectiveness of pharmaceutical treat-
ments in reducing exacerbations was obtained from three
published meta-analyses. RESULTS: Compared to 1996, the
improved pharmaceutical treatment decreased other OAD treat-
ment costs in 2005 by 33.7 (95% CI: 19.4–50.9) million euros
explaining 42.1% of the decrease in secondary health care costs
of OAD in Finland. When adjusting for the increase in the
number of patients, the extra costs of new pharmaceutical treat-
ments were 5.1 million euros. Thus the increase in pharmaceu-
tical costs was offset more than 6-fold by the reduction in the
secondary health care costs. CONCLUSION: The OAD treat-
ment costs in Finland have decreased signiﬁcantly as a result of
increased use of more effective pharmaceuticals. When pharma-
ceuticals are properly evaluated as one part of the treatment
process, the expressed concerns over the increasing pharmaceu-
tical costs seem to be unfounded in the case of OAD.
PRS6
ECONOMIC BURDEN OF DISEASE OF PULMONARY ARTERIAL
HYPERTENSION IN GERMANY:AN INTERIM ANALYSIS OF
RESOURCE UTILISATION
Ehlken B1, Plesnila Frank C1, Ghofrani HA2, Grimminger F2,
Hoeper MM3, Stähler G4,Wilkens H5, Berger K1, Resch A6
1MERG—Medical Economics Research Group, München, Germany,
2University Hospital Giessen and Marburg, Giessen, Germany,
3Hannover Medical School, Hanover, Germany, 4Klinik Löwenstein,
Löwenstein, Germany, 5University Hospitals of the Saarland,
Homburg/Saar, Germany, 6Pﬁzer Deutschland GmbH, Karlsruhe,
Germany
OBJECTIVES: To describe health care provision and resource
consumption in patients with pulmonary arterial hypertension
(PAH) in Germany. METHODS: A multi-centre, cross-sectional,
retrospective and prospective study was conducted which
addressed PAH care in hospitals and in the ambulant setting
taking into account the patients’ perspective. Study period
covered 15 months. In hospitals, chart abstraction was accom-
plished 12 months retrospectively and 3 months prospectively. A
GPs’ questionnaire covered health care utilisation in the ofﬁce-
based sector and two patient questionnaires were applied to
collect data on health status, resource consumption (over 3
months), and quality of life. RESULTS: Ten hospitals enrolled
150 patients with PAH; data of 118 patients (treated October
2004-December 2006) were considered within this interim analy-
sis. Response rate of GP questionnaire was 52%, of patient
questionnaires 85% (1st questionnaire) and 76% (2nd question-
naire). Mean age of patients was 55 years (SD 14), 72% were
female. 60% suffered from idiopathic PAH and 40% from PAH
mainly associated with collagen vascular diseases (37%), con-
genital systemic-to-pulmonary shunts (26%), or portal hyperten-
sion (22%). Mean duration from occurrence of ﬁrst symptoms
until diagnosis was 2.3 years (SD 4.4). Within 15 months mean
number of GP visits was 23.1 (SD 16.2); mean number of
hospital visits was 4.5. 44% of patients were hospitalised
(mean length of stay: 7.1 days SD 6.1). Hospitalisation
with surgical interventions (5% of hospital stays) occurred
for port-transplantation or catheter replacement. 59% of
patients received anticoagulants, 60% diuretics, 27% calcium-
antagonists, 66% endothelin-receptor antagonists, 20% inhala-
tive prostacyclin analogues, and 25% PDE5 inhibitors. 10% of
patients participated in rehabilitation with a mean length of stay
of 30.1 days (SD 11.3). CONCLUSION: This analysis is the ﬁrst
step in a comprehensive study on health care provision and
economic burden of PAH in Germany. In a second step outcomes,
e.g. disease severity and quality of life, will be assessed.
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OBJECTIVES: The objective of this study was to test the ability
of Diagnostic Cost Groups (DCGs), RxGroups, and prior cost
risk models to identify high risk patients within the Texas
Medicaid Chronic Obstructive Pulmonary Disease (COPD)
population who could beneﬁt from case management interven-
tion. METHODS: DCGs, RxGroups, and prior cost risk models
were used to predict future medical costs. ICD-9 diagnostic
codes, NDC drug codes and 2001 total health care costs were
input into the risk models. The study included Texas Medicaid
patients under the age of 65 who had an inpatient diagnoses of
COPD in 2000 and were continuously enrolled in Medicaid from
2000–2002 (n = 7967). The risk models predicted total health
care costs for 2002. Predicted costs were compared to actual
2002 costs using R2 and mean absolute prediction error. Predic-
tion of high cost cases were analyzed using the positive predictive
value (PPV) of the top 5% of high cost patients. RESULTS: The
R2 was 0.035 for the DCG inpatient + RxGroups model and
0.033 for the prior cost model. For the top 5% of high cost
patients the DCG + RxGroups model had a PPV of 20.5% (82/
399). PPV for the prior cost model was 33.1%(132/399). The
mean absolute prediction error was $7293 for the DCG
inpatient + RxGroups model and $7429 for the prior cost model.
CONCLUSION: Diagnosis-based risk adjustment models using
only inpatient and pharmacy data may not be as useful as prior
cost data when attempting to identify future high cost cases
among Texas Medicaid COPD patients. A combination of
diagnosis-based risk adjustment models and prior cost data may
prove to be the most effective way to identify COPD candidates
for case management.
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